Cargando…
Multi-omics to predict acute radiation esophagitis in patients with lung cancer treated with intensity-modulated radiation therapy
PURPOSE: The study aimed to predict acute radiation esophagitis (ARE) with grade ≥ 2 for patients with locally advanced lung cancer (LALC) treated with intensity-modulated radiation therapy (IMRT) using multi-omics features, including radiomics and dosiomics. METHODS: 161 patients with stage IIIA−I...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024847/ https://www.ncbi.nlm.nih.gov/pubmed/36935504 http://dx.doi.org/10.1186/s40001-023-01041-6 |
_version_ | 1784909198437384192 |
---|---|
author | Zheng, Xiaoli Guo, Wei Wang, Yunhan Zhang, Jiang Zhang, Yuanpeng Cheng, Chen Teng, Xinzhi Lam, Saikit Zhou, Ta Ma, Zongrui Liu, Ruining Wu, Hui Ge, Hong Cai, Jing Li, Bing |
author_facet | Zheng, Xiaoli Guo, Wei Wang, Yunhan Zhang, Jiang Zhang, Yuanpeng Cheng, Chen Teng, Xinzhi Lam, Saikit Zhou, Ta Ma, Zongrui Liu, Ruining Wu, Hui Ge, Hong Cai, Jing Li, Bing |
author_sort | Zheng, Xiaoli |
collection | PubMed |
description | PURPOSE: The study aimed to predict acute radiation esophagitis (ARE) with grade ≥ 2 for patients with locally advanced lung cancer (LALC) treated with intensity-modulated radiation therapy (IMRT) using multi-omics features, including radiomics and dosiomics. METHODS: 161 patients with stage IIIA−IIIB LALC who received chemoradiotherapy (CRT) or radiotherapy by IMRT with a prescribed dose from 45 to 70 Gy from 2015 to 2019 were enrolled retrospectively. All the toxicity gradings were given following the Common Terminology Criteria for Adverse Events V4.0. Multi-omics features, including radiomics, dosiomics (including dose−volume histogram dosimetric parameters), were extracted based on the planning CT image and three-dimensional dose distribution. All data were randomly divided into training cohorts (N = 107) and testing cohorts (N = 54). In the training cohorts, features with reliably high outcome relevance and low redundancy were selected under random patient subsampling. Four classification models (using clinical factors (CF) only, using radiomics features (RFs) only, dosiomics features (DFs) only, and the hybrid features (HFs) containing clinical factors, radiomics and dosiomics) were constructed employing the Ridge classifier using two-thirds of randomly selected patients as the training cohort. The remaining patient was treated as the testing cohort. A series of models were built with 30 times training–testing splits. Their performances were assessed using the area under the ROC curve (AUC) and accuracy. RESULTS: Among all patients, 51 developed ARE grade ≥ 2, with an incidence of 31.7%. Next, 8990 radiomics and 213 dosiomics features were extracted, and 3, 6, 12, and 13 features remained after feature selection in the CF, DF, RF and DF models, respectively. The RF and HF models achieved similar classification performance, with the training and testing AUCs of 0.796 ± 0.023 (95% confidence interval (CI [0.79, 0.80])/0.744 ± 0.044 (95% CI [0.73, 0.76]) and 0.801 ± 0.022 (95% CI [0.79, 0.81]) (p = 0.74), respectively. The model performances using CF and DF features were poorer, with training and testing AUCs of 0.573 ± 0.026 (95% CI [0.56, 0.58])/ 0.509 ± 0.072 (95% CI [0.48, 0.53]) and 0.679 ± 0.027 (95% CI [0.67, 0.69])/0.604 ± 0.041 (95% CI [0.53, 0.63]) compared with the above two models (p < 0.001), respectively. CONCLUSIONS: In LALC patients treated with CRT IMRT, the ARE grade ≥ 2 can be predicted using the pretreatment radiotherapy image features. To predict ARE, the multi-omics features had similar predictability with radiomics features; however, the dosiomics features and clinical factors had a limited classification performance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01041-6. |
format | Online Article Text |
id | pubmed-10024847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100248472023-03-20 Multi-omics to predict acute radiation esophagitis in patients with lung cancer treated with intensity-modulated radiation therapy Zheng, Xiaoli Guo, Wei Wang, Yunhan Zhang, Jiang Zhang, Yuanpeng Cheng, Chen Teng, Xinzhi Lam, Saikit Zhou, Ta Ma, Zongrui Liu, Ruining Wu, Hui Ge, Hong Cai, Jing Li, Bing Eur J Med Res Research PURPOSE: The study aimed to predict acute radiation esophagitis (ARE) with grade ≥ 2 for patients with locally advanced lung cancer (LALC) treated with intensity-modulated radiation therapy (IMRT) using multi-omics features, including radiomics and dosiomics. METHODS: 161 patients with stage IIIA−IIIB LALC who received chemoradiotherapy (CRT) or radiotherapy by IMRT with a prescribed dose from 45 to 70 Gy from 2015 to 2019 were enrolled retrospectively. All the toxicity gradings were given following the Common Terminology Criteria for Adverse Events V4.0. Multi-omics features, including radiomics, dosiomics (including dose−volume histogram dosimetric parameters), were extracted based on the planning CT image and three-dimensional dose distribution. All data were randomly divided into training cohorts (N = 107) and testing cohorts (N = 54). In the training cohorts, features with reliably high outcome relevance and low redundancy were selected under random patient subsampling. Four classification models (using clinical factors (CF) only, using radiomics features (RFs) only, dosiomics features (DFs) only, and the hybrid features (HFs) containing clinical factors, radiomics and dosiomics) were constructed employing the Ridge classifier using two-thirds of randomly selected patients as the training cohort. The remaining patient was treated as the testing cohort. A series of models were built with 30 times training–testing splits. Their performances were assessed using the area under the ROC curve (AUC) and accuracy. RESULTS: Among all patients, 51 developed ARE grade ≥ 2, with an incidence of 31.7%. Next, 8990 radiomics and 213 dosiomics features were extracted, and 3, 6, 12, and 13 features remained after feature selection in the CF, DF, RF and DF models, respectively. The RF and HF models achieved similar classification performance, with the training and testing AUCs of 0.796 ± 0.023 (95% confidence interval (CI [0.79, 0.80])/0.744 ± 0.044 (95% CI [0.73, 0.76]) and 0.801 ± 0.022 (95% CI [0.79, 0.81]) (p = 0.74), respectively. The model performances using CF and DF features were poorer, with training and testing AUCs of 0.573 ± 0.026 (95% CI [0.56, 0.58])/ 0.509 ± 0.072 (95% CI [0.48, 0.53]) and 0.679 ± 0.027 (95% CI [0.67, 0.69])/0.604 ± 0.041 (95% CI [0.53, 0.63]) compared with the above two models (p < 0.001), respectively. CONCLUSIONS: In LALC patients treated with CRT IMRT, the ARE grade ≥ 2 can be predicted using the pretreatment radiotherapy image features. To predict ARE, the multi-omics features had similar predictability with radiomics features; however, the dosiomics features and clinical factors had a limited classification performance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01041-6. BioMed Central 2023-03-19 /pmc/articles/PMC10024847/ /pubmed/36935504 http://dx.doi.org/10.1186/s40001-023-01041-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zheng, Xiaoli Guo, Wei Wang, Yunhan Zhang, Jiang Zhang, Yuanpeng Cheng, Chen Teng, Xinzhi Lam, Saikit Zhou, Ta Ma, Zongrui Liu, Ruining Wu, Hui Ge, Hong Cai, Jing Li, Bing Multi-omics to predict acute radiation esophagitis in patients with lung cancer treated with intensity-modulated radiation therapy |
title | Multi-omics to predict acute radiation esophagitis in patients with lung cancer treated with intensity-modulated radiation therapy |
title_full | Multi-omics to predict acute radiation esophagitis in patients with lung cancer treated with intensity-modulated radiation therapy |
title_fullStr | Multi-omics to predict acute radiation esophagitis in patients with lung cancer treated with intensity-modulated radiation therapy |
title_full_unstemmed | Multi-omics to predict acute radiation esophagitis in patients with lung cancer treated with intensity-modulated radiation therapy |
title_short | Multi-omics to predict acute radiation esophagitis in patients with lung cancer treated with intensity-modulated radiation therapy |
title_sort | multi-omics to predict acute radiation esophagitis in patients with lung cancer treated with intensity-modulated radiation therapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024847/ https://www.ncbi.nlm.nih.gov/pubmed/36935504 http://dx.doi.org/10.1186/s40001-023-01041-6 |
work_keys_str_mv | AT zhengxiaoli multiomicstopredictacuteradiationesophagitisinpatientswithlungcancertreatedwithintensitymodulatedradiationtherapy AT guowei multiomicstopredictacuteradiationesophagitisinpatientswithlungcancertreatedwithintensitymodulatedradiationtherapy AT wangyunhan multiomicstopredictacuteradiationesophagitisinpatientswithlungcancertreatedwithintensitymodulatedradiationtherapy AT zhangjiang multiomicstopredictacuteradiationesophagitisinpatientswithlungcancertreatedwithintensitymodulatedradiationtherapy AT zhangyuanpeng multiomicstopredictacuteradiationesophagitisinpatientswithlungcancertreatedwithintensitymodulatedradiationtherapy AT chengchen multiomicstopredictacuteradiationesophagitisinpatientswithlungcancertreatedwithintensitymodulatedradiationtherapy AT tengxinzhi multiomicstopredictacuteradiationesophagitisinpatientswithlungcancertreatedwithintensitymodulatedradiationtherapy AT lamsaikit multiomicstopredictacuteradiationesophagitisinpatientswithlungcancertreatedwithintensitymodulatedradiationtherapy AT zhouta multiomicstopredictacuteradiationesophagitisinpatientswithlungcancertreatedwithintensitymodulatedradiationtherapy AT mazongrui multiomicstopredictacuteradiationesophagitisinpatientswithlungcancertreatedwithintensitymodulatedradiationtherapy AT liuruining multiomicstopredictacuteradiationesophagitisinpatientswithlungcancertreatedwithintensitymodulatedradiationtherapy AT wuhui multiomicstopredictacuteradiationesophagitisinpatientswithlungcancertreatedwithintensitymodulatedradiationtherapy AT gehong multiomicstopredictacuteradiationesophagitisinpatientswithlungcancertreatedwithintensitymodulatedradiationtherapy AT caijing multiomicstopredictacuteradiationesophagitisinpatientswithlungcancertreatedwithintensitymodulatedradiationtherapy AT libing multiomicstopredictacuteradiationesophagitisinpatientswithlungcancertreatedwithintensitymodulatedradiationtherapy |